Dependence on joint research, development and sales relationships with DAIICHI SANKYO COMPANY,LIMITED.
First written in FY2023. 1 of 3 entries say "Mitigated", first in FY2026. Latest entry: FY2026.
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「The joint research and development agreement with DAIICHI SANKYO COMPANY,LIMITED. ended at the end of March 2026 because its purpose was achieved when Reheart obtained conditional and time-limited marketing approval in Japan in March 2026.」
The joint research and development relationship with DAIICHI SANKYO COMPANY,LIMITED. ended after approval was obtained, partially reducing dependence on the former joint development and sales relationship. The intellectual-property license continues, leaving risks relating to license terms. - FY2024-Q2Change in classification as an affiliated companyAnnual report
「As stated in the timely disclosure dated 27 June 2023 titled “Notice Concerning Change in Other Affiliated Company,” DAIICHI SANKYO COMPANY,LIMITED. ceased to qualify as one of our other affiliated companies.」
The company stated that DAIICHI SANKYO COMPANY,LIMITED. ceased to qualify as an other affiliated company. No termination of the joint research, development or sales relationship, or material change in the risk, was reported. - FY2023First statedAnnual report
「We plan to maintain a good relationship with DAIICHI SANKYO COMPANY,LIMITED. and continue joint research and development and other activities. However, if the agreement is revised on terms unfavorable to us or terminated, research and development could be delayed and sales targets could be missed, materially affecting our business performance and financial condition.」
DAIICHI SANKYO COMPANY,LIMITED. provides research and development funding, personnel and licenses, and also holds an option on domestic sales rights.